FRANKFURT (Reuters) - German drugmaker Merck KGaA has withdrawn its second attempt to win European approval for use of its Erbitux drug against lung cancer, capping a string of setbacks in its drug development. Merck said on Tuesday it gave up the new attempt it made in March to win EU approval for the use of its second best-selling drug Erbitux against lung cancer, which had targeted a quarter of the patients it had initially tried to address. ... Click here to read the rest
No comments:
Post a Comment